DEF 14A

Company

Viking Therapeutics, Inc.

Filed

April 7, 2022

Period of Report

May 24, 2022

Accession Number

0001564590-22-013875

A DEF 14A is a proxy statement sent to shareholders before an annual meeting. It covers executive compensation, board elections, and shareholder votes. Learn more about DEF 14A filings →